Fig. 5From: Establishing a reasonable price for an orphan drug(Sources: NICE (https://www.nice.org.uk/), SMC (https://www.scottishmedicines.org.uk/) and authors’ calculations)Adjusted cost-effectiveness thresholds and NICE-SMC decisions to recommend. The line that relates population sizes to adjusted CET by connecting our adjusted CETs of this figure goes to the point of the ultra-orphan CET (£937 k/QALY)Back to article page